Effect of denosumab on glucose metabolism in postmenopausal osteoporotic women with prediabetes: a study protocol for a 12-month multicenter, open-label, randomized controlled trial.

Abstract

BACKGROUND:

Participants with prediabetes are at a high risk of developing type 2 diabetes (T2D). Recent studies have suggested that blocking the receptor activator of nuclear factor-κB ligand (RANKL) may improve glucose metabolism and delay the development of T2D. However, the effect of denosumab, a fully human monoclonal antibody that inhibits RANKL, on glycemic parameters in the prediabetes population is uncertain. We aim to examine the effect of denosumab on glucose metabolism in postmenopausal women with osteoporosis and prediabetes.

METHODS:

This is a 12-month multicenter, open-label, randomized controlled trial involving postmenopausal women who have been diagnosed with both osteoporosis and prediabetes. Osteoporosis is defined by the World Health Organization (WHO) as a bone mineral density T score of ≤ - 2.5, as measured by dual-energy X-ray absorptiometry (DXA). Prediabetes is defined as (i) a fasting plasma glucose level of 100-125 mg/dL, (ii) a 2-hour plasma glucose level of 140-199 mg/dL, or (iii) a glycosylated hemoglobin A1c (HbA1c) level of 5.7-6.4%. A total of 346 eligible subjects will be randomly assigned in a 1:1 ratio to receive either subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg every week for 12 months. The primary outcome is the change in HbA1c levels from baseline to 12 months. Secondary outcomes include changes in fasting and 2-hour blood glucose levels, serum insulin levels, C-peptide levels, and insulin sensitivity from baseline to 12 months, and the incidence of T2D at the end of the study. Follow-up visits will be scheduled at 3, 6, 9, and 12 months.

DISCUSSION:

This study aims to provide evidence on the efficacy of denosumab on glucose metabolism in postmenopausal women with osteoporosis and prediabetes. The results derived from this clinical trial may provide insight into the potential of denosumab in preventing T2D in high-risk populations.

TRIAL REGISTRATION:

This study had been registered in the Chinese Clinical Trials Registry.

REGISTRATION NUMBER:

ChiCTR2300070789 on April 23, 2023. https://www.chictr.org.cn .

• Authors: Yilin Wang, Yu Jiang, Jia Li, Xisheng Lin, Yan Luo, Shuhuai Tan, Haohan Yang, Zefu Gao, Xiang Cui, Pengbin Yin, Dan Kong, Yuan Gao, Yu Cheng, Licheng Zhang, Peifu Tang, Houchen Lyu
• Journal: Trials (Trials) Vol. 24 Issue 1 Pg. 812 (Dec 18 2023) ISSN: 1745-6215 [Electronic] England
• PMID: 38111052 (Publication Type: Clinical Trial Protocol, Journal Article)
• Copyright: © 2023. The Author(s).

Chemical References

• Blood Glucose
• Bone Density Conservation Agents
• Denosumab
• Glycated Hemoglobin
• RANK Ligand

Topics

• Female
• Humans
• Blood Glucose
• Bone Density
• Bone Density Conservation Agents (pharmacology)
• Denosumab (pharmacology)
• Diabetes Mellitus, Type 2 (complications, diagnosis, drug therapy)
• Glycated Hemoglobin
• Multicenter Studies as Topic
• Osteoporosis (diagnosis, drug therapy)
• Osteoporosis, Postmenopausal (diagnosis, drug therapy)
• Postmenopause
• Prediabetic State (diagnosis, drug therapy)
• Randomized Controlled Trials as Topic
• RANK Ligand